Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Stopped development program of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems

Conditions

• Acute Myeloid Leukemia (AML)
• High-risk Myelodysplastic Syndrome (MDS)

Interventions

• DRUG: Volasertib
• DRUG: Cytarabine
• DRUG: Daunorubicin
• DRUG: Mitoxantrone

Sponsor

University of Ulm